Changes in Blood DNA CpG Methylation Levels in Response to Methadone Maintenance Treatment: Epigenome-Wide Longitudinal Study
Epigenomes · 05.03.2026 · 10 (1) · 18
DOI: 10.3390/epigenomes10010018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epigenomes, online erschienen am 05.03.2026. Verfasst von Orna Levran und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY 10065, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dr. Miriam and Sheldon G. Adelson Medical Research Foundation., Dr. Miriam and Sheldon G. Adelson Medical Research Foundation.
Abstract (Originalsprache)
Background/Objectives: Methadone maintenance treatment (MMT) is one of the major pharmacotherapies for opioid use disorder. The underlying mechanisms of addiction and the treatment response are only partially understood. The study’s main goal was to identify differential DNA CpG methylation that occurred in response to MMT.
Methods
Toward this goal, we have conducted a longitudinal epigenome-wide study of blood samples from 64 patients at the beginning and after 1–3 years of MMT, using a linear mixed model.
Results
A total of 1881 differentially methylated probes (DMPs) were identified (FDR < 0.05), controlling for sex, age, estimates of blood cell proportions, and the first two principal components based on genome-wide SNP genotypes. Among the genes annotated to the top DMPs are DGLUCY, NXNL2, SOX10, and NPAS3. Several genes associated with substance use disorder were annotated by the identified DMPs, including ADORA2A, BDNF, CACNA1D, CREB1, CRHR1, CRY1, DNMT3B, GABRD, GNAS, GRIP1, OXR1, PRKACB, SCN2A, and SCN3A. The most overrepresented pathway is the small GTPase-mediated signal transduction pathway, and the most overrepresented process is the actin cytoskeleton organization.
Conclusions
The study provides preliminary insight into the epigenetic effect of MMT. Future studies will have to confirm the DMPs, assess their impact on gene expression, and determine their clinical relevance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY 10065, USA.
- Dr. Miriam & Sheldon G. Adelson Clinic for Drug Abuse Treatment & Research, Tel Aviv Sourasky University Medical Center, Tel Aviv 6423906, Israel.
- AccuraScience LLC, Johnston, IA 50131, USA.
- Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.
- Sagol School of Neuroscience, Tel Aviv University, Tel Aviv 6997801, Israel.
ORCID-Profile: Orna Levran, Einat Peles
Förderung
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation.
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Zitieren
APA
Levran, O., Kim, Y., Li, J., Sason, A., Adelson, M., & Peles, E. (2026). Changes in Blood DNA CpG Methylation Levels in Response to Methadone Maintenance Treatment: Epigenome-Wide Longitudinal Study. Epigenomes, 10(1), 18. https://doi.org/10.3390/epigenomes10010018
Vancouver
Levran O, Kim Y, Li J, Sason A, Adelson M, Peles E. Changes in Blood DNA CpG Methylation Levels in Response to Methadone Maintenance Treatment: Epigenome-Wide Longitudinal Study. Epigenomes. 2026;10(1):18. doi:10.3390/epigenomes10010018
BibTeX
@article{Levran2026,
author = {Levran, Orna and Kim, Yuli and Li, Justin and Sason, Anat and Adelson, Miriam and Peles, Einat},
title = {Changes in Blood DNA CpG Methylation Levels in Response to Methadone Maintenance Treatment: Epigenome-Wide Longitudinal Study},
journal = {Epigenomes},
year = {2026},
volume = {10},
number = {1},
pages = {18},
doi = {10.3390/epigenomes10010018}
}
EUVIMED